Information Provided By: 
Fly News Breaks for December 12, 2019
ZBH
Dec 12, 2019 | 07:01 EDT
Wells Fargo analyst Lawrence Biegelsen raised his price target for Zimmer Biomet to $165 from $158 and maintained an Overweight rating as part of his broader Medical Technology industry research note. Biegelsen says Zimmer Biomet shares trade at roughly a 20% discount to its large-cap MedTech peer group and he believes the discount will narrow as the company benefits from the leadership of its commercially-driven CEO, Bryan Hanson, operational issues continue to be resolved and its pipeline begins to be fully appreciated.
News For ZBH From the Last 2 Days
There are no results for your query ZBH
